Your Health, We Care
Revumenib is a menin inhibitor indicated for the following conditions:
Treatment of relapsed or refractory acute leukemia in adult and pediatric patients aged 1 year and older, with confirmed lysine methyltransferase 2A (KMT2A) translocation detected by an FDA-authorized test.
Treatment of relapsed or refractory acute myeloid leukemia in adult and pediatric patients aged 1 year and older, with susceptible nucleophosmin 1 (NPM1) mutation and in the absence of other satisfactory alternative treatment options.
FDA，2025.10
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
